Baseline Biomarkers for Outcome of Melanoma Patients Treated with Pembrolizumab
University of Tübingen · German Cancer Research Center · +26 more institutions
Abstract
PURPOSE: Biomarkers for outcome after immune-checkpoint blockade are strongly needed as these may influence individual treatment selection or sequence. We aimed to identify baseline factors associated with overall survival (OS) after pembrolizumab treatment in melanoma patients. EXPERIMENTAL DESIGN: Serum lactate dehydrogenase (LDH), routine blood count parameters, and clinical characteristics were investigated in 616 patients. Endpoints were OS and best overall response following pembrolizumab treatment. Kaplan-Meier analysis and Cox regression were applied for survival analysis. RESULTS: Relative eosinophil count (REC) ≥1.5%, relative lymphocyte count (RLC) ≥17.5%, ≤2.5-fold elevation of LDH, and the absence…
Citation impact
- FWCI
- 34.11
- Percentile
- 100%
- References
- 46
Authors
27- BWBenjamin WeideCorresponding
University of Tübingen
- AMAlexander Martens
University of Tübingen
- JCJessica C. Hassel
German Cancer Research Center, Heidelberg University, University Hospital Heidelberg, National Center for Tumor Diseases, Deutschen Konsortium für Translationale Krebsforschung
- CBCarola Berking
German Cancer Research Center, München Klinik, Deutschen Konsortium für Translationale Krebsforschung
- MAMichael A. Postow
Cornell University, Kettering University
Topics & keywords
- Pembrolizumab
- Medicine
- Internal medicine
- Oncology
- Lactate dehydrogenase
- Cohort
- Melanoma
- Proportional hazards model
- Good health and well-being